Immunomedics (IMMU) Misses Q2 EPS by 50c
Tweet
Share
E-mailGet Alerts IMMU Hot Sheet
Price: $87.86 --0%
Financial Fact:
Total costs and expenses: 15.69M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Financial Fact:
Total costs and expenses: 15.69M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Immunomedics (NASDAQ: IMMU) reported Q2 EPS of ($0.84), $0.50 worse than the analyst estimate of ($0.34).
As of December 31, 2018, the Company had $497.8 million in cash, cash equivalents, and marketable securities, which it believes is adequate to support its clinical development plan for sacituzumab govitecan; further build its clinical and manufacturing infrastructure and fund its operations through 2020.
For earnings history and earnings-related data on Immunomedics (IMMU) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
